Lisinopril versus ramipril
Searched over 200M research papers
Summary
10 papers analyzed
Some studies suggest lisinopril is more effective in promoting endothelial progenitor cell migration and reducing cardiovascular morbidity and mortality, while other studies indicate ramipril is better tolerated and has higher patient adherence in hypertension treatment.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta19 papers analyzed
Comparative Analysis of Lisinopril and Ramipril
Introduction to ACE Inhibitors: Lisinopril and Ramipril
Angiotensin-converting enzyme (ACE) inhibitors, such as lisinopril and ramipril, are commonly prescribed for managing cardiovascular conditions, including hypertension, heart failure, and post-myocardial infarction care. This article synthesizes recent research comparing the efficacy, safety, and additional benefits of lisinopril and ramipril.
Efficacy in Enhancing Endothelial Progenitor Cell (EPC) Migration
Research indicates that both lisinopril and ramipril enhance the migratory capabilities of endothelial progenitor cells (EPCs), which are crucial for vascular repair and regeneration. However, high-dose lisinopril (100 mM) significantly outperforms ramipril in promoting EPC migration, suggesting a superior efficacy in this context .
Cardiovascular Outcomes in Post-Myocardial Infarction Patients
A meta-analysis of four randomized, controlled studies evaluated the efficacy of lisinopril and ramipril in post-acute myocardial infarction (AMI) patients with and without metabolic syndrome. The findings revealed that lisinopril significantly reduced the 1-year risk of cardiovascular events compared to placebo, whereas ramipril was associated with a higher risk of such events . This suggests that lisinopril may offer better cardiovascular protection in post-AMI patients.
Blood Pressure Management in Hypertension
In a randomized, double-blind trial comparing the efficacy of lisinopril and ramipril in patients with mild to moderate hypertension, ramipril demonstrated a slightly higher response rate and greater reduction in blood pressure compared to lisinopril. Additionally, ramipril was better tolerated, with fewer adverse events reported. This indicates that ramipril might be more effective and better tolerated for hypertension management.
Protection Against Endothelial Injury
Both lisinopril and ramipril have shown protective effects against free radical-induced endothelial injury. Studies indicate that these ACE inhibitors can prevent the conversion of vasodilatory responses to vasoconstriction and maintain serotonin uptake in endothelial cells, highlighting their role in preserving endothelial function.
Patient Adherence and Persistence
Patient adherence to medication is crucial for effective hypertension management. A study on fixed-dose combinations of ramipril/amlodipine and lisinopril/amlodipine found that patients on the ramipril combination had significantly higher adherence rates over one year compared to those on the lisinopril combination. This suggests that ramipril may be more favorable in terms of long-term patient adherence.
Mortality and Heart Failure Outcomes
In patients with chronic heart failure, a propensity score-matched cohort study found no significant difference in all-cause mortality between lisinopril and ramipril when given at equivalent doses. This supports the notion that both ACE inhibitors are equally effective in managing heart failure.
Conclusion
Both lisinopril and ramipril are effective ACE inhibitors with distinct advantages depending on the clinical context. Lisinopril shows superior efficacy in enhancing EPC migration and reducing cardiovascular events post-AMI, while ramipril demonstrates better blood pressure control and patient adherence. Clinicians should consider these differences when choosing the appropriate ACE inhibitor for their patients.
Sources and full results
Most relevant research papers on this topic
